Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer
Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma
SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present one oral presentation and two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.
The abstracts will be available on the ASCO meeting website. The posters will be available online at Erasca.com/events/presentations following the presentations.
Presentation Details
- Abstract 3517 - Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study
Date/Time: Monday, June 3, 2024, 1:15 PM-2:45 PM CDT
Type: Rapid Oral Abstract
Session: Gastrointestinal Cancer—Colorectal and Anal
Presenter: Dr. Aparna Parikh, Massachusetts General Hospital
Location: McCormick Place Convention Center, Arie Crown Theater
- Abstract TPS3178 - An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1)
Date/Time: Saturday, June 1, 2024, 9:00 AM-12:00 PM CDT
Type: Poster Session
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Dr. Alex Spira, Next Oncology Virginia
Location: McCormick Place Convention Center, Exhibit Hall/Hall A, Poster Board 314a
- Abstract 11522 – Preliminary ...